• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    AstraZeneca PLC – ADR to Join the NASDAQ-100 Index Beginning February 22, 2022

    2/10/22 5:00:00 PM ET
    $AZN
    $NDAQ
    $XLNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Bankers/Brokers/Service
    Finance
    Get the next $AZN alert in real time by email

    NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that AstraZeneca PLC – ADR (NASDAQ:AZN), will become a component of the NASDAQ-100 Index® (NASDAQ:NDX) and the NASDAQ-100 Equal Weighted Index (NASDAQ:NDXE) prior to market open on Tuesday, February 22, 2022. AstraZeneca PLC – ADR will replace Xilinx, Inc. (NASDAQ:XLNX) in the NASDAQ-100 Index® and the NASDAQ-100 Equal Weighted Index.

    For more information about the company, go to https://www.astrazeneca.com.

    About Nasdaq

    Nasdaq (NASDAQ:NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software and services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com.

    Media Contact

    Emily Pan

    [email protected]

    +1 (646) 637-3964

    Issuer & Investor Contact

    Index Client Services

    [email protected]

    The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither The NASDAQ OMX Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq's proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

    - NDAQG -



    Primary Logo

    Get the next $AZN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AZN
    $NDAQ
    $XLNX

    CompanyDatePrice TargetRatingAnalyst
    Nasdaq Inc.
    $NDAQ
    4/17/2025$91.00Neutral → Buy
    Redburn Atlantic
    AstraZeneca PLC
    $AZN
    4/15/2025$75.00Outperform
    Exane BNP Paribas
    Nasdaq Inc.
    $NDAQ
    4/8/2025$74.00Overweight → Equal-Weight
    Morgan Stanley
    AstraZeneca PLC
    $AZN
    2/13/2025Neutral → Buy
    UBS
    AstraZeneca PLC
    $AZN
    2/12/2025Overweight
    Morgan Stanley
    Nasdaq Inc.
    $NDAQ
    1/8/2025$80.00 → $98.00Hold → Buy
    Deutsche Bank
    Nasdaq Inc.
    $NDAQ
    11/25/2024Outperform
    William Blair
    AstraZeneca PLC
    $AZN
    11/20/2024Sell → Neutral
    UBS
    More analyst ratings

    $AZN
    $NDAQ
    $XLNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Nasdaq Inc.

      SC 13G/A - NASDAQ, INC. (0001120193) (Subject)

      11/12/24 3:53:01 PM ET
      $NDAQ
      Investment Bankers/Brokers/Service
      Finance
    • SEC Form SC 13G filed by Nasdaq Inc.

      SC 13G - NASDAQ, INC. (0001120193) (Subject)

      11/8/24 10:52:39 AM ET
      $NDAQ
      Investment Bankers/Brokers/Service
      Finance
    • Amendment: SEC Form SC 13G/A filed by Nasdaq Inc.

      SC 13G/A - NASDAQ, INC. (0001120193) (Subject)

      11/4/24 1:18:47 PM ET
      $NDAQ
      Investment Bankers/Brokers/Service
      Finance

    $AZN
    $NDAQ
    $XLNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $AZN
    $NDAQ
    $XLNX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Chair and CEO Friedman Adena T covered exercise/tax liability with 8,057 shares, decreasing direct ownership by 0.42% to 1,924,903 units (SEC Form 4)

      4 - NASDAQ, INC. (0001120193) (Issuer)

      4/7/25 4:39:14 PM ET
      $NDAQ
      Investment Bankers/Brokers/Service
      Finance
    • Pres. Market Platforms Tal Cohen covered exercise/tax liability with 1,564 shares, decreasing direct ownership by 0.81% to 191,742 units (SEC Form 4)

      4 - NASDAQ, INC. (0001120193) (Issuer)

      4/7/25 4:34:59 PM ET
      $NDAQ
      Investment Bankers/Brokers/Service
      Finance
    • Pres. Capital Access Platforms Griggs Pc Nelson covered exercise/tax liability with 1,564 shares, decreasing direct ownership by 0.71% to 219,405 units (SEC Form 4)

      4 - NASDAQ, INC. (0001120193) (Issuer)

      4/7/25 4:30:40 PM ET
      $NDAQ
      Investment Bankers/Brokers/Service
      Finance
    • IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial

      Patients lived significantly longer without high-risk disease recurrence or progression after one year of IMFINZI treatment plus Bacillus Calmette-Guérin (BCG) induction and maintenance therapy vs. BCG alone Positive high-level results from the POTOMAC Phase III trial showed one year of treatment with AstraZeneca's IMFINZI® (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) compared to BCG induction and maintenance therapy alone.​ The trial was not statistically powered to formally test ov

      5/9/25 7:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11

      AstraZeneca and Daiichi Sankyo's ENHERTU followed by THP showed an improved safety profile vs. standard of care First Phase III trial to demonstrate benefit of ENHERTU in early breast cancer Positive high-level results from the DESTINY-Breast11 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pathologic complete response (pCR) rate versus standard of care (dose-dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP]) when used in the neoadjuvant setting (before surgery) in patients with high-risk, locally advanced HER2-positi

      5/7/25 7:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ENHERTU® Followed by THP Before Surgery Showed Statistically Significant and Clinically Meaningful Improvement in Pathologic Complete Response in Patients With High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial

      Daiichi Sankyo and AstraZeneca's ENHERTU followed by THP showed an improved safety profile versus standard of care First phase 3 trial to demonstrate benefit of ENHERTU in early breast cancer Results will be shared with regulatory authorities Positive topline results from the DESTINY-Breast11 phase 3 trial showed ENHERTU® (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pathologic complete response (pCR) rate versus standard of care (dose-dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP]) when used in the neoadjuvant setting (before surgery) in patients w

      5/7/25 2:30:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    $NDAQ
    $XLNX
    SEC Filings

    See more
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      5/7/25 9:53:18 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      5/6/25 9:15:27 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      5/2/25 9:38:38 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    $NDAQ
    $XLNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • NASDAQ upgraded by Redburn Atlantic with a new price target

      Redburn Atlantic upgraded NASDAQ from Neutral to Buy and set a new price target of $91.00

      4/17/25 8:27:31 AM ET
      $NDAQ
      Investment Bankers/Brokers/Service
      Finance
    • Exane BNP Paribas initiated coverage on AstraZeneca with a new price target

      Exane BNP Paribas initiated coverage of AstraZeneca with a rating of Outperform and set a new price target of $75.00

      4/15/25 12:40:56 PM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NASDAQ downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded NASDAQ from Overweight to Equal-Weight and set a new price target of $74.00

      4/8/25 9:21:41 AM ET
      $NDAQ
      Investment Bankers/Brokers/Service
      Finance

    $AZN
    $NDAQ
    $XLNX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Zollar Alfred W bought $203,970 worth of shares (2,542 units at $80.24), increasing direct ownership by 5% to 49,293 units (SEC Form 4)

      4 - NASDAQ, INC. (0001120193) (Issuer)

      11/14/24 4:29:16 PM ET
      $NDAQ
      Investment Bankers/Brokers/Service
      Finance
    • Torgeby Johan bought $705,880 worth of shares (14,000 units at $50.42), increasing direct ownership by 165% to 22,466 units (SEC Form 4)

      4 - NASDAQ, INC. (0001120193) (Issuer)

      10/25/23 4:02:10 PM ET
      $NDAQ
      Investment Bankers/Brokers/Service
      Finance

    $AZN
    $NDAQ
    $XLNX
    Leadership Updates

    Live Leadership Updates

    See more
    • Nasdaq Appoints Brandis DeSimone as New Head of East Coast Listings

      The appointment strengthens Nasdaq's commitment to supporting companies throughout their corporate lifecycle Nasdaq is the exchange of choice for new listings and exchange transfers in the US, raising $22.97 Billion in IPO proceeds across 180 listings in 2024 and celebrating over 500 transfers to Nasdaq since 2005 NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced the appointment of Brandis DeSimone as Senior Vice President, Head of East Coast Listings. Under the recently established regional operational structure, this appointment further strengthens Nasdaq's commitment to supporting companies throughout their corporate lifecycle and deepening client rel

      3/3/25 10:40:42 AM ET
      $NDAQ
      Investment Bankers/Brokers/Service
      Finance
    • Nasdaq Welcomed 171 IPOs in 2024

      Leading U.S. exchange by number of IPOs and proceeds raised for the sixth consecutive year Featured the largest IPO and switch Over 500 exchange transfers to Nasdaq since 2005 NEW YORK, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) announced today that in 2024, it welcomed 171 initial public offerings (IPOs), raising a total of $22.7 billion. A total of 123 operating companies and 48 SPACs listed on Nasdaq in 2024, representing an 81% win rate of Nasdaq-eligible IPOs in the U.S. market, and extending Nasdaq's leadership to 44 consecutive quarters. In addition to IPOs, there were 23 exchange transfers to Nasdaq, representing $180 billion in market cap, including Palantir,

      12/17/24 8:05:00 AM ET
      $NDAQ
      Investment Bankers/Brokers/Service
      Finance
    • AppLovin Corporation to Join the Nasdaq-100 Index® Beginning November 18, 2024

      NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that AppLovin Corporation (NASDAQ:APP), will become a component of the Nasdaq-100 Index® (NASDAQ:NDX) and the Nasdaq-100 Equal Weighted™ Index (NASDAQ:NDXE) prior to market open on Monday, November 18, 2024. AppLovin Corporation will replace Dollar Tree, Inc. (NASDAQ:DLTR) in the Nasdaq-100 Index® and the Nasdaq-100 Equal Weighted™ Index. Dollar Tree, Inc. will also be removed from the Nasdaq-100 Ex-Tech Sector™ Index (NASDAQ:NDXX), the Nasdaq-100 ESG™ Index (NASDAQ:NDXESG), the Nasdaq-100 Sustainable ESG Select™ Index (NASDAQ:NDXSES) , the Nasdaq-100 ex Top 30™ Index (NASDAQ:NDX), and the Nasdaq-100 ex T

      11/8/24 8:00:00 PM ET
      $APP
      $DLTR
      $NDAQ
      Computer Software: Programming Data Processing
      Technology
      Department/Specialty Retail Stores
      Consumer Discretionary

    $AZN
    $NDAQ
    $XLNX
    Financials

    Live finance-specific insights

    See more
    • AstraZeneca's Q1 2025 Financial Results

      Growth momentum and pipeline delivery set AstraZeneca on a strong trajectory towards 2030 ambition AstraZeneca: Revenue and EPS summary   Q1 2025 % Change       $m Actual CER1       - Product Sales 12,875 6 9       - Alliance Revenue 639 40 42       Product Revenue2 13,514 7 10       Collaboration Revenue 74 64 64       Total Revenue 13,588 7 10       Reported EPS ($) 1.88 34 32       Core3 EPS ($) 2.49 21 21       Key performance elements for Q1 2025 (Growth numbers at constant exchange

      4/29/25 2:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance
    • Nasdaq Announces 13% Increase in Quarterly Dividend to $0.27 Per Share

      NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Nasdaq, Inc. (NASDAQ:NDAQ) has declared a regular quarterly dividend of $0.27 per share on the company's outstanding common stock, a 13% increase from the previous quarter. The dividend is payable on June 27, 2025 to shareholders of record at the close of business on June 13, 2025. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by the Board of Directors. About Nasdaq Nasdaq (NASDAQ:NDAQ) is a leading global technology company serving corporate clients, investment managers, banks, brokers, and exchange operators as they navigate and intera

      4/24/25 7:01:00 AM ET
      $NDAQ
      Investment Bankers/Brokers/Service
      Finance